Sign In
24 Jun 2008 11:28
ο»Ώ
Ark Therapeutics Group plc
24 June 2008
Notification of Major Interests in Shares
Β 1Β Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
ARK THERAPEUTICS GROUP PLC
2.Β Reason for the notification (please tick the appropriate box or boxes):
|
An acquisition or disposal of voting rights: |
( ) |
An acquisition or disposal of financial instruments which mayΒ
result in the acquisition of shares already issued to which votingΒ
|
rights are attached |
( ) |
|
An event changing the breakdown of voting rights:Β |
( ) |
|
Other (please specify): |
(x) |
Voting rights in the issuer named in 1 above are no longerΒ
managed by the Company named in 3 below. These sharesΒ
have been transferred in specie for management by a third party.
3.Β Full name of person(s) subject to the notification obligation:
New Star Asset Management Limited
4.Β Full name of shareholder(s) (if different from 3):
N/A
Β
5.Β Date of the transaction and date on which the threshold is crossed or reached if different:
2 June 2008
6.Β Date on which issuer notified:
24 June 2008
Β
7.Β Threshold(s) that is/are crossed or reached:
5%
8.Β Notified details:
A:Β Voting rights attached to shares
|
Class/type of shares: |
GB0034251727 |
Situation previous to the triggering transaction:
|
Number of shares: |
10,454,881 |
|
Number of voting rights: |
10,454,881 |
Resulting situation after the triggering transaction:
|
Number of shares: |
9,871,441 |
Number of voting rights:Β
Direct:
|
Indirect: |
9,871,441 |
% of voting rights:
Direct:
|
Indirect: |
4.77% |
B:Β Financial Instruments:
Resulting situation after the triggering transaction:
Type of financial instrument:
Expiration date:
Exercise/conversion period/date:
Β
Number of voting rights that may be acquiredΒ
if the instrument is exercised/ converted:
% of voting rights:
Total (A+B):
|
Number of voting rights: |
9,871,441 |
|
% of voting rights: |
4.77% |
9.Β Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Proxy Voting:
Β 10.Β Name of the proxy holder:
N/A
11.Β Number of voting rights proxy holder will cease to hold:
N/A
Β 12.Β Date on which proxy holder will cease to hold voting rights:
N/A
13.Β Additional information:
N/A
Β 14.Β Contact name:
Not advised
15.Β Contact telephone number:
Not advised
16. Contact name and telephone at issuer:
MARTYN WILLIAMS
Company Secretary
Ark Therapeutics Group plc
020 7388 7722
24 June 2008
Follow the stocks
